(Q45372811)

13 December 2017

Cross-protection against influenza virus infection by intranasal administration of M1-based vaccine with chitosan as an adjuvant (English)

1 reference

13 December 2017

1 reference

2

Quanjiao Chen

1 reference

13 December 2017

Zhiwei Sui

1

1 reference

13 December 2017

Fang Fang

series ordinal

3

1 reference

13 December 2017

Mei Zheng

series ordinal

4

1 reference

13 December 2017

Ze Chen

series ordinal

5

1 reference

13 December 2017

language of work or name

English

0 references

publication date

24 September 2010

1 reference

13 December 2017

9

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

13 December 2017

28

1 reference

13 December 2017

48

1 reference

13 December 2017

7690-7698

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.019

13 December 2017

1 reference

Improved design and intranasal delivery of an M2e-based human influenza A vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.019

Influenza: old and new threats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.019

Mortality associated with influenza and respiratory syncytial virus in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.019

Realities and enigmas of human viral influenza: pathogenesis, epidemiology and control

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.019

Protective immunity against influenza A virus induced by immunization with DNA plasmid containing influenza M gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.019

DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.019

Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.019

The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.019

Nasal-associated lymphoid tissue is a mucosal inductive site for virus-specific humoral and cellular immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.019

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.019

Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.019

Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.019

Th immune response induced by H pylori vaccine with chitosan as adjuvant and its relation to immune protection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.019

Production, Properties, and Some New Applications of Chitin and Its Derivatives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.019

Carbohydrate biopolymers enhance antibody responses to mucosally delivered vaccine antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.019

Stimulation of mucosal and systemic antibody responses against Bordetella pertussis filamentous haemagglutinin and recombinant pertussis toxin after nasal administration with chitosan in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.019

A mucosal vaccine against diphtheria: formulation of cross reacting material (CRM(197)) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.019

Effective nasal influenza vaccine delivery using chitosan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.019

ProJuvant (Pluronic F127/chitosan) enhances the immune response to intranasally administered tetanus toxoid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.019

Chitosan and its use as a pharmaceutical excipient

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.019

Chitosan: some pharmaceutical and biological aspects--an update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.019

A special report on the chitosan-based hemostatic dressing: experience in current combat operations.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.019

Chitosan solution enhances both humoral and cell-mediated immune responses to subcutaneous vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.019

Comparing the ability of a series of viral protein-expressing plasmid DNAs to protect against H5N1 influenza virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.019

Protection against avian influenza H9N2 virus challenge by immunization with hemagglutinin- or neuraminidase-expressing DNA in BALB/c mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.019

Protection against influenza virus challenge by topical application of influenza DNA vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.019

Comparison of the ability of viral protein-expressing plasmid DNAs to protect against influenza

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.019

Protection against influenza virus infection in BALB/c mice immunized with a single dose of neuraminidase-expressing DNAs by electroporation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.019

Purification of influenza virus glycoproteins for the preparation and standardization of immunological potency testing reagents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.019

Vaccination with hemagglutinin or neuraminidase DNA protects BALB/c mice against influenza virus infection in presence of maternal antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.019

Maternal immunization with both hemagglutinin- and neuraminidase-expressing DNAs provides an enhanced protection against a lethal influenza virus challenge in infant and adult mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.019

A universal influenza A vaccine based on the extracellular domain of the M2 protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.019

Modified M2 proteins produce heterotypic immunity against influenza A virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.019

Detection of influenza viruses through selective adsorption and detection of the M-protein antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.019

Chitosan as a novel nasal delivery system for vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.019

Chitosan microspheres enhance the immunogenicity of an Ag85B-based fusion protein containing multiple T-cell epitopes of Mycobacterium tuberculosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.019

Mutant influenza A virus nucleoprotein is preferentially localized in the cytoplasm and its immunization in mice shows higher immunogenicity and cross-reactivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.019

Protective cross-reactive cellular immunity to lethal A/Goose/Guangdong/1/96-like H5N1 influenza virus is correlated with the proportion of pulmonary CD8(+) T cells expressing gamma interferon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.019

Multiple functions of immunoglobulin A in mucosal defense against viruses: an in vitro measles virus model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.019

Intraepithelial cell neutralization of HIV-1 replication by IgA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.019

Rotavirus anti-VP6 secretory immunoglobulin A contributes to protection via intracellular neutralization but not via immune exclusion.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.019

Immunoglobulin A antibodies against internal HIV-1 proteins neutralize HIV-1 replication inside epithelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.019

10.1016/J.VACCINE.2010.09.019

7 January 2021

Identifiers

DOI

1 reference

13 December 2017

1 reference